St. Joseph's Hospital and Medical Center, Phoenix
Trial Pipeline
Repurposing Siponimod for Alzheimer's Disease
NCT06639282
Working Memory Training in Patients with Mild Cognitive Impairment
NCT06734286
PREVENT ALL ALS Study
NCT06581861
ASSESS ALL ALS Study
NCT06578195
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
NCT06072586
Gentamicin Bladder Instillation on CAUTI
NCT06332040
Time Restricted Eating in Alzheimer's Disease
NCT06429124
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
NCT03014687
Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)
NCT02759887
Barrow Nasal Inventory Survey
NCT01322945
Identification of Novel Molecular Markers for Vasospasm
NCT02389634
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 4 | 2 |
What the Pipeline for St. Joseph's Hospital and Medical Center, Phoenix Shows
According to the ClinicalTrials.gov registry, St. Joseph's Hospital and Medical Center, Phoenix is linked to 39 US clinical trials across every stage of research activity. Of those, 36 studies are currently recruiting — about 92% of the sponsor's indexed portfolio — and 3 are already marked complete, representing roughly 8% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for St. Joseph's Hospital and Medical Center, Phoenix reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for St. Joseph's Hospital and Medical Center, Phoenix is Mild Cognitive Impairment (MCI) with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.